LifeVantage Corporation (FRA:L2T1)

Germany flag Germany · Delayed Price · Currency is EUR
4.200
+0.200 (5.00%)
Last updated: Feb 20, 2026, 4:39 PM CET
Market Cap52.67M -80.8%
Revenue (ttm)178.90M -1.0%
Net Income6.69M +7.1%
EPS0.51 +6.9%
Shares Outn/a
PE Ratio7.87
Forward PE8.28
Dividend0.16 (3.70%)
Ex-Dividend DateDec 1, 2025
Volume200
Average Volume102
Open4.180
Previous Close4.000
Day's Range4.180 - 4.200
52-Week Range3.400 - 17.500
Betan/a
RSI46.77
Earnings DateFeb 4, 2026

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatig... [Read more]

Industry Pharmaceutical Preparations
CEO Steven Fife
Employees 235
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol L2T1
Full Company Profile

Financial Performance

In fiscal year 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.

Financial numbers in USD Financial Statements